Processa Pharmaceuticals
PCSA
12 hedge funds and large institutions have $498K invested in Processa Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
20% more funds holding
Funds holding: 10 → 12 (+2)
11% more capital invested
Capital invested by funds: $448K → $498K (+$49.9K)
2.55% more ownership
Funds ownership: 6.68% → 9.23% (+2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$55.2K |
| 2 |
CCM
Connective Capital Management
Palo Alto,
California
|
+$37.6K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$34.4K |
| 4 |
Jane Street
New York
|
+$34.3K |
| 5 |
SG
StoneX Group
New York
|
+$29.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$7.3K |
| 2 |
Citigroup
New York
|
-$35 |
| 3 |
Wells Fargo
San Francisco,
California
|
-$15 |
PCSA Hedge Fund Activity: Q2 2026 in Review
12 of the 8,330 institutional investors tracked by Wall St. Rank reported a position in Processa Pharmaceuticals (PCSA) for Q2 2026, worth a combined $498K — up 11% from $448K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new PCSA positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $55.2K. The largest seller was Geode Capital Management, cutting an estimated $7.3K.
- 12 institutional investors held Processa Pharmaceuticals (PCSA) as of Q2 2026, up from 10 in Q1 2026.
- Funds reported $498K of Processa Pharmaceuticals stock for Q2 2026, up 11% quarter-over-quarter.
- 4 funds opened new Processa Pharmaceuticals positions in Q2 2026 and 2 closed out, a net change of +2 holders.
- The largest Processa Pharmaceuticals buyer in Q2 2026 was Citadel Advisors, an estimated $55.2K added.
- The largest Processa Pharmaceuticals seller in Q2 2026 was Geode Capital Management, an estimated $7.3K sold.
Based on aggregated 13F filings for Q2 2026.